NEW DELHI: Eli Lilly, the US pharmaceutical giant that gained widespread attention globally with its weight-loss treatments, plans to launch its blockbuster drug - Tirzepatide - in India in 2025.

Eli Lilly and Novo Nordisk dominate the market for weight loss drugs, and demand for their products has surpassed supply in recent times. Lilly’s weight loss portfolio has already delivered ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide ...

Eli Lilly (NYSE: LLY) has produced a wide variety of treatments for various illnesses throughout its 145-year history. But this big pharma company truly took center stage over the past year or so ...

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated approval—which allows the BTK inhibitor to be used following anoth ...

It cited avocados as an example. Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks that beat the market in the last 3 years. The broader market has ...

Eli Lilly and Co. on Thursday unveiled a $3 billion expansion of its facility in the Kenosha County. The announcement marked one of the biggest business developments in southeastern Wisconsin ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that its weight loss treatment, Zepbound (tirzepatide), outperformed Novo ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...